 | • レポートコード：D0JU09098 • 出版社/出版日：Transparency Market Research / 2020年2月7日 • レポート形態：英文、PDF、182ページ • 納品方法：Eメール • 産業分類：診断 |
| Single User | ￥857,660 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,301,660 (USD8,795) | ▷ お問い合わせ |
| Corporate License | ￥1,745,660 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートでは、神経栄養性角膜炎の世界市場について調査・分析し、序論、仮定・調査手法、エグゼクティブサマリー、市場動向、市場概要、治療種類別（薬物（人工涙液、組換えヒト神経成長因子点眼薬、抗生物質、包帯コンタクトレンズ、その他）、外科的介入（足裏、羊膜移植、その他））分析、ステージ別（ステージI、ステージII、ステージIII）分析、地域別分析、競争状況などの構成でお届けいたします。 ・序論 ・仮定・調査手法 ・エグゼクティブサマリー ・市場動向 ・市場概要 ・神経栄養性角膜炎の世界市場：治療種類別（薬物（人工涙液、組換えヒト神経成長因子点眼薬、抗生物質、包帯コンタクトレンズ、その他）、外科的介入（足裏、羊膜移植、その他）） ・神経栄養性角膜炎の世界市場：ステージ別（ステージI、ステージII、ステージIII） ・神経栄養性角膜炎の世界市場：地域別 ・競争状況 |
Neurotrophic Keratitis Market – Scope of the Report
TMR’s report on the global neurotrophic keratitis market studies past as well as current growth trends and opportunities to gain valuable insights of these indicators for the market during the forecast period of 2019–2027. The report provides the revenue of the global neurotrophic keratitis market for the period 2017–2027, considering 2018 as the base year and 2027 as the forecast year. The report also provides the compound annual growth rate (CAGR) of the global neurotrophic keratitis market during the forecast period.
The report has been prepared after an extensive research. Primary research involved bulk of research efforts, wherein analysts carried out interviews with industry leaders and opinion makers. Extensive secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the global neurotrophic keratitis market.
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various phenomenon in the global neurotrophic keratitis market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on changing competitive dynamics in the global neurotrophic keratitis market. These indices serve as valuable tools for existing players in the neurotrophic keratitis market as well as for entities interested in entering the global market.
The report delves into the competitive landscape of the global neurotrophic keratitis market. Key players operating in the global neurotrophic keratitis market have been identified, and each one of these has been profiled for their distinguishing business attributes. Company overview, financial standings, recent developments, and SWOT are some of the attributes of players in the global neurotrophic keratitis market that have been profiled in this report.
レポート目次1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Neurotrophic Keratitis Market
4. Market Overview
4.1. Introduction
4.1.1. Treatment Type Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Neurotrophic Keratitis Market Analysis and Forecast, 2017–2027
4.4.1. Market Revenue Projections (US$ Mn)
4.5. Porter’s Five Force Analysis
5. Market Outlook
5.1. Disease Prevalence & Incidence Rate globally with key countries / Region
5.2. Pipeline Analysis
5.3. Key Industry Developments
6. Global Neurotrophic Keratitis Market Analysis and Forecast, by Treatment Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Treatment Type, 2017–2027
6.3.1. Drugs
6.3.1.1. Artificial Tears
6.3.1.2. Recombinant Human Nerve Growth Factors Eye Drop
6.3.1.3. Oral Antibiotics
6.3.1.4. Bandage Contact Lens
6.3.1.5. Others
6.3.2. Surgical Intervention
6.3.2.1. Tarsorrhaphy
6.3.2.2. Amniotic Membrane Transplantation
6.3.2.3. Others
6.4. Market Attractiveness, by Treatment Type
7. Global Neurotrophic Keratitis Market Analysis and Forecast, by Stage
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Stage, 2017–2027
7.3.1. Stage I
7.3.2. Stage II
7.3.3. Stage III
7.4. Market Attractiveness Analysis, by Stage
8. Global Neurotrophic Keratitis Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness Analysis, by Country/Region
9. North America Neurotrophic Keratitis Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast By Treatment Type, 2017–2027
9.2.1. Drugs
9.2.1.1. Artificial Tears
9.2.1.2. Recombinant Human Nerve Growth Factors Eye Drop
9.2.1.3. Oral Antibiotics
9.2.1.4. Bandage Contact Lens
9.2.1.5. Others
9.2.2. Surgical Intervention
9.2.2.1. Tarsorrhaphy
9.2.2.2. Amniotic Membrane Transplantation
9.2.2.3. Others
9.3. Market Value Forecast, by Stage, 2017–2027
9.3.1. Stage I
9.3.2. Stage II
9.3.3. Stage III
9.4. Market Value Forecast, by Country, 2017–2027
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1. By Treatment Type
9.5.2. By Stage
9.5.3. By Country
10. Europe Neurotrophic Keratitis Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Treatment Type, 2017–2027
10.2.1. Drugs
10.2.1.1. Artificial Tears
10.2.1.2. Recombinant Human Nerve Growth Factors Eye Drop
10.2.1.3. Oral Antibiotics
10.2.1.4. Bandage Contact Lens
10.2.1.5. Others
10.2.2. Surgical Intervention
10.2.2.1. Tarsorrhaphy
10.2.2.2. Amniotic Membrane Transplantation
10.2.2.3. Others
10.3. Market Value Forecast, by Stage, 2017–2027
10.3.1. Stage I
10.3.2. Stage II
10.3.3. Stage III
10.4. Market Value Forecast, by Country/Sub-region, 2017–2027
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Rest of Europe
10.5. Market Attractiveness Analysis
10.5.1. By Treatment Type
10.5.2. By Stage
10.5.3. By Country/Sub-region
11. Asia Pacific Neurotrophic Keratitis Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Treatment Type, 2017–2027
11.2.1. Drugs
11.2.1.1. Artificial Tears
11.2.1.2. Recombinant Human Nerve Growth Factors Eye Drop
11.2.1.3. Oral Antibiotics
11.2.1.4. Bandage Contact Lens
11.2.1.5. Others
11.2.2. Surgical Intervention
11.2.2.1. Tarsorrhaphy
11.2.2.2. Amniotic Membrane Transplantation
11.2.2.3. Others
11.3. Market Value Forecast, by Stage, 2017–2027
11.3.1. Stage I
11.3.2. Stage II
11.3.3. Stage III
11.4. Market Value Forecast, by Country/Sub-region, 2017–2027
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Market Attractiveness Analysis
11.5.1. By Treatment Type
11.5.2. By Stage
11.5.3. By Country/Sub-region
12. Latin America Neurotrophic Keratitis Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Treatment Type, 2017–2027
12.2.1. Drugs
12.2.1.1. Artificial Tears
12.2.1.2. Recombinant Human Nerve Growth Factors Eye Drop
12.2.1.3. Oral Antibiotics
12.2.1.4. Bandage Contact Lens
12.2.1.5. Others
12.2.2. Surgical Intervention
12.2.2.1. Tarsorrhaphy
12.2.2.2. Amniotic Membrane Transplantation
12.2.2.3. Others
12.3. Market Value Forecast, by Stage, 2017–2027
12.3.1. Stage I
12.3.2. Stage II
12.3.3. Stage III
12.4. Market Value Forecast, by Country/Sub-region, 2017–2027
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Market Attractiveness Analysis
12.5.1. By Treatment Type
12.5.2. By Stage
12.5.3. By Country/Sub-region
13. Middle East & Africa Neurotrophic Keratitis Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Treatment Type, 2017–2027
13.2.1. Drugs
13.2.1.1. Artificial Tears
13.2.1.2. Recombinant Human Nerve Growth Factors Eye Drop
13.2.1.3. Oral Antibiotics
13.2.1.4. Bandage Contact Lens
13.2.1.5. Others
13.2.2. Surgical Intervention
13.2.2.1. Tarsorrhaphy
13.2.2.2. Amniotic Membrane Transplantation
13.2.2.3. Others
13.3. Market Value Forecast, by Stage, 2017–2027
13.3.1. Stage I
13.3.2. Stage II
13.3.3. Stage III
13.4. Market Value Forecast, by Country/Sub-region, 2017–2027
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Market Attractiveness Analysis
13.5.1. By Treatment Type
13.5.2. By Stage
13.5.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player – Competition Matrix (By Tier and Size of companies)
14.2. Market Share/Position Analysis, by Company, 2018
14.3. Company Profiles
14.3.1. Dompe farmaceutici S.p.A.
14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2. Growth Strategies
14.3.1.3. SWOT Analysis
14.3.2. Allergan
14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2. Growth Strategies
14.3.2.3. SWOT Analysis
14.3.3. ReGenTree, LLC
14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2. Growth Strategies
14.3.3.3. SWOT Analysis
14.3.4. Alcon
14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2. Growth Strategies
14.3.4.3. SWOT Analysis
14.3.5. Bausch & Lomb Incorporated (Bausch Health Companies Inc.)
14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2. Growth Strategies
14.3.5.3. SWOT Analysis
14.3.6. CONTACARE
14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2. Growth Strategies
14.3.6.3. SWOT Analysis
14.3.7. ROHTO Pharmaceutical Co., Ltd.
14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.7.2. Growth Strategies
14.3.7.3. SWOT Analysis
14.3.8. Pfizer, Inc.
14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.8.2. Growth Strategies
14.3.8.3. SWOT Analysis
14.3.9. Neuroptika
14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.9.2. Growth Strategies
14.3.9.3. SWOT Analysis
14.3.10. Santen Pharmaceutical Co., Ltd.
14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.10.2. Growth Strategies
14.3.10.3. SWOT Analysis
14.3.11. Johnson & Johnson
14.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.11.2. Growth Strategies
14.3.11.3. SWOT Analysis
14.3.12. Grand Pharma (China) Co., Ltd.
14.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.12.2. Growth Strategies
14.3.12.3. SWOT Analysis
14.3.13. Zhejiang CONBA Pharmaceutical Co., Ltd.
14.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.13.2. Growth Strategies
14.3.13.3. SWOT Analysis
List of TablesTable 01: Neurotrophic Keratitis Pipeline Analysis - Phase III and Phase II
Table 02: Neurotrophic Keratitis Pipeline Analysis - Phase I
Table 03: Global Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2027
Table 04: Global Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Drugs, 2017–2027
Table 05: Global Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Surgical Intervention, 2017–2027
Table 06: Global Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Stage, 2017–2027
Table 07: Global Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Region, 2017–2027
Table 08: North America Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Country, 2017–2027
Table 09: North America Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2027
Table 10: North America Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Drugs, 2017–2027
Table 11: North America Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Surgical Intervention, 2017–2027
Table 12: North America Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Stage, 2017–2027
Table 13: Europe Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 14: Europe Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2027
Table 15: Europe Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Drugs, 2017–2027
Table 16: Europe Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Surgical Intervention, 2017–2027
Table 17: Europe Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Stage, 2017–2027
Table 18: Asia Pacific Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 19: Asia Pacific Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2027
Table 20: Asia Pacific Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Drugs, 2017–2027
Table 21: Asia Pacific Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Surgical Intervention, 2017–2027
Table 22: Asia Pacific Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Stage, 2017–2027
Table 23: Latin America Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 24: Latin America Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2027
Table 25: Latin America Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Drugs, 2017–2027
Table 26: Latin America Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Surgical Intervention, 2017–2027
Table 27: Latin America Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Stage, 2017–2027
Table 28: Middle East & Africa Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 29: Middle East & Africa Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2027
Table 30: Middle East & Africa Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Drugs, 2017–2027
Table 31: Middle East & Africa Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Surgical Intervention, 2017–2027
Table 32: Middle East & Africa Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Stage, 2017–2027